Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (91-100 of 186) with videos related to

Pageof 19
Sort By:
International Cancer Conference Journal|December 15, 2025
Resistance mechanism to pembrolizumab in <i>DEK</i>-<i>AFF2</i> fusion-associated sinonasal squamous cell carcinomaShogen Boku, Takao Fujisawa, Shigenori Kadowaki, et al.
BMC Cancer|July 25, 2020
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancerMasaaki Miyo, Takeshi Kato, Takayuki Yoshino, et al.
International Journal of Clinical Oncology|December 23, 2024
A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical deviceHideaki Bando, Yoichi Naito, Tomoyuki Yamada, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 10, 2016
Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II studyNozomu Fuse, Hideaki Bando, Keisho Chin, et al.
Cancer Science|June 15, 2021
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNAKuniko Sunami, Hideaki Bando, Yasushi Yatabe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2024
Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease AssayYoshiaki Nakamura, Yuichiro Tsukada, Nobuhisa Matsuhashi, et al.
Therapeutic Advances in Medical Oncology|February 12, 2024
Chronological improvement of survival in patients with advanced gastric cancer over 15 yearsTakatsugu Ogata, Yukiya Narita, Isao Oze, et al.
Annals of Surgical Oncology|November 21, 2018
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 GastrectomyYoshiaki Nakamura, Takeharu Yamanaka, Keisho Chin, et al.
Cancer Science|March 2, 2024
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potentialTadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2016
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinomaHironaga Satake, Makoto Tahara, Satoshi Mochizuki, et al.
Pageof 19

Showing results (91-100 of 186) with videos related to

Sort By:
Pageof 19
International Cancer Conference Journal|December 15, 2025
Resistance mechanism to pembrolizumab in <i>DEK</i>-<i>AFF2</i> fusion-associated sinonasal squamous cell carcinomaShogen Boku, Takao Fujisawa, Shigenori Kadowaki, et al.
BMC Cancer|July 25, 2020
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancerMasaaki Miyo, Takeshi Kato, Takayuki Yoshino, et al.
International Journal of Clinical Oncology|December 23, 2024
A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical deviceHideaki Bando, Yoichi Naito, Tomoyuki Yamada, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 10, 2016
Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II studyNozomu Fuse, Hideaki Bando, Keisho Chin, et al.
Cancer Science|June 15, 2021
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNAKuniko Sunami, Hideaki Bando, Yasushi Yatabe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2024
Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease AssayYoshiaki Nakamura, Yuichiro Tsukada, Nobuhisa Matsuhashi, et al.
Therapeutic Advances in Medical Oncology|February 12, 2024
Chronological improvement of survival in patients with advanced gastric cancer over 15 yearsTakatsugu Ogata, Yukiya Narita, Isao Oze, et al.
Annals of Surgical Oncology|November 21, 2018
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 GastrectomyYoshiaki Nakamura, Takeharu Yamanaka, Keisho Chin, et al.
Cancer Science|March 2, 2024
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potentialTadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2016
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinomaHironaga Satake, Makoto Tahara, Satoshi Mochizuki, et al.
Pageof 19